who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

How AbbVie (ABBV) makes money: Q3 2026 revenue breakdown

US GAAP, Q3 2026 · quarter ended 09/30/2026 · released Oct 30

Net earnings attributable to AbbVie Inc.

$4,218M

up ×23 y/y

Net revenues

$17,404M

up 10.3% y/y

Operating earnings

$6,267M

up 229% y/y

Next report

~ Feb 3

not announced yet

The quarter in brief

AbbVie's Q3 2026 net revenues rose 10.3% to $17,404M, with immunology at $9,165M (+16.3%) and neuroscience at $3,389M (+19.4%). GAAP net earnings were $4,218M against $186M a year earlier, with acquired IPR&D and milestones at $216M against $2,680M.

Key growth driver: Skyrizi — the largest product line: $5,776M, +22.7% y/y. · by the Q3 2026 report

How does AbbVie make money?

AbbVie brought in $17.4 billion of revenue in Q3 2026, up 10.3% year over year. The largest source was Immunology: $9.16 billion, or 53% of the total, followed by Neuroscience ($3.39B, 19%) and Oncology ($1.70B, 10%); other lines add the remaining 18%. Net income for the quarter was $4.22 billion.

Revenue by source, Q3 2026
  • Immunology$9.16B · 53% · +16.3%
  • Neuroscience$3.39B · 19% · +19.4%
  • Oncology$1.70B · 10% · +0.8%
  • Aesthetics$1.18B · 7% · −1.4%
  • All other (remainder)$1.01B · 6%
  • Other Key Products$965M · 6% · −4.1%

Shares of $17.4B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.

All figures in $M.

Sankey diagram of ABBV (AbbVie) earnings report for Q3 2026: revenue, costs and profitSkyrizi$5,776 · +22.7%Rinvoq$2,706 · +23.9%Humira$683 · −31.2%Vraylar$1,068 · +14.3%Botox Therapeutic$1,080 · +9.8%Ubrelvy$449 · +26.9%Qulipta$398 · +38.2%Vyalev$286 · >100%Other Neuroscience$108 · −23.9%Venclexta$803 · +10.7%Imbruvica$522 · −26.1%Elahere$224 · +31.0%Epkinly$108 · +57.7%Other Oncology$39 · >100%Botox Cosmetic$669 · +4.9%Juvederm Collection$222 · −11.9%Other Aesthetics$285 · −6.0%Mavyret$265 · −15.1%Creon$361 · −2.2%Linzess$339 · +4.2%Immunology$9,165 · +16.3%Neuroscience$3,389 · +19.4%Oncology$1,696 · +0.8%Aesthetics$1,176 · −1.4%Other KeyProducts$965 · −4.1%All other(remainder)$1,013Net revenues$17,404 · +10.3%Cost of productssold$4,285 · −19.2%Gross profit$13,119 · +25.3%Other operatingincome$18 · vs $0Selling, generalandadministrative$4,087 · +14.5%Research anddevelopment$2,567 · +10.7%Acquired IPR&Dand milestones$216 · −91.9%Operatingearnings$6,267 · +229%Interest expense,net$700 · +4.9%Other expense,net$738 · +41.1%Earnings beforeincome taxexpense$4,829 · +576%Income tax expense$609 · +15.8%12.6% effective rateNet earnings attributableto noncontrolling interest$2 · vs $2Net earnings attributableto AbbVie Inc.$4,218 · ×23$2.37/sh · 24.2% margin
Sankey diagram of ABBV (AbbVie) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Skyrizi$5,776 · +22.7%
Rinvoq$2,706 · +23.9%
Humira$683 · −31.2%
Vraylar$1,068 · +14.3%
Botox Therapeutic$1,080 · +9.8%
Ubrelvy$449 · +26.9%
Qulipta$398 · +38.2%
Vyalev$286 · >100%
Other Neuroscience$108 · −23.9%
Venclexta$803 · +10.7%
Imbruvica$522 · −26.1%
Elahere$224 · +31.0%
Epkinly$108 · +57.7%
Other Oncology$39 · >100%
Botox Cosmetic$669 · +4.9%
Juvederm Collection$222 · −11.9%
Other Aesthetics$285 · −6.0%
Mavyret$265 · −15.1%
Creon$361 · −2.2%
Linzess$339 · +4.2%
Immunology$9,165 · +16.3%
Neuroscience$3,389 · +19.4%
Oncology$1,696 · +0.8%
Aesthetics$1,176 · −1.4%
Other Key Products$965 · −4.1%
All other (remainder)$1,013
Net revenues$17,404 · +10.3%
Cost of products sold$4,285 · −19.2%
Gross profit$13,119 · +25.3%
Other operating income$18 · vs $0
Selling, general and administrative$4,087 · +14.5%
Research and development$2,567 · +10.7%
Acquired IPR&D and milestones$216 · −91.9%
Operating earnings$6,267 · +229%
Interest expense, net$700 · +4.9%
Other expense, net$738 · +41.1%
Earnings before income tax expense$4,829 · +576%
Income tax expense$609 · +15.8% · 12.6% effective rate
Net earnings attributable to noncontrolling interest$2 · vs $2
Net earnings attributable to AbbVie Inc.$4,218 · ×23 · $2.37/sh · 24.2% margin

Verdict: AbbVie's Q3 2026 net revenues rose 10.3% to $17,404M, with immunology at $9,165M (+16.3%) and neuroscience at $3,389M (+19.4%). GAAP net earnings were $4,218M against $186M a year earlier, with acquired IPR&D and milestones at $216M against $2,680M.

AbbVie raised its 2026 adjusted diluted EPS guidance from $13.76 - $13.96 to $13.95 - $13.99, including a $0.69 per share unfavorable impact from acquired IPR&D and milestones incurred through Q3. The quarterly dividend rises 5.2% from $1.73 to $1.82 per share, beginning with the dividend payable on February 16, 2027. For the nine months, net revenues were $49,396 million and diluted EPS was $4.79 versus $1.34.

Source and notation

y/y for products, portfolios and net revenues is reported, as in the company's Key Product Revenues table (not operational). All other (remainder) = net revenues minus the five portfolios of that table. Gross profit = net revenues minus cost of products sold. Imbruvica international and Epkinly U.S. revenues reflect profit sharing. Source: AbbVie press release, 8-K EX-99.1 of 10/30/2026 (SEC EDGAR).

Open as an image: AbbVie (ABBV), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “AbbVie (ABBV) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/abbv. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/abbv"><img src="https://whoreportstoday.com/t/abbv/img/abbvie-abbv-earnings-sankey.png" alt="AbbVie (ABBV) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/abbv">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/abbv/img/abbvie-abbv-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/abbv">AbbVie (ABBV) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. · Text: Wikipedia, CC BY-SA 4.0, abridged

AbbVie produces drugs to treat a wide range of medical issues. Market share (US pharma & biotech): ≈9% by TTM revenue.

Company reports

Q3 2026latest breakdownAbbVie's Q3 2026 net revenues rose 10.3% to $17,404M, with immunology at $9,165M (+16.3%) and neuroscience at $3,389M…
Q2 2026The business is healthy — +10% growth and 48% adj. operating margin

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2026EPS (non-GAAP) $13.95–13.99 (raised)revenue $61.2BEPS (GAAP) $2.36—

Same quarter a year ago (ended December 31, 2025): revenue $16.62B, EPS (GAAP) $1.02

How we calculate

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Oct 30, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

ABBV earnings history: past report dates

Oct 30, 2026 Fri7:51 ambefore market openSep 30, 2026$17.4B+10% y/y$2.37
Jul 31, 2026 Fri7:51 ambefore market openJun 30, 2026$17.0B+10% y/y$2.03+290% y/y
Apr 29, 2026 Wed7:50 ambefore market openMar 31, 2026$15.0B+12% y/y$0.39−46% y/y
Feb 4, 2026 Wed7:54 ambefore market openDec 31, 2025$16.6B+10% y/y$1.02
Oct 31, 2025 Fri7:51 ambefore market openSep 30, 2025$15.8B+9% y/y$0.10−89% y/y
Jul 31, 2025 Thu7:48 ambefore market openJun 30, 2025$15.4B+7% y/y$0.52−32% y/y
Apr 25, 2025 Fri7:48 ambefore market openMar 31, 2025$13.3B+8% y/y$0.72−6% y/y
Jan 31, 2025 Fri7:42 ambefore market openDec 31, 2024$15.1B+6% y/y−$0.02
Oct 30, 2024 Wed7:43 ambefore market openSep 30, 2024$14.5B+4% y/y$0.88−12% y/y
Jul 25, 2024 Thu7:41 ambefore market openJun 30, 2024$14.5B+4% y/y$0.77−32% y/y
Apr 26, 2024 Fri7:43 ambefore market openMar 31, 2024$12.3B+1% y/y$0.77+492% y/y
Feb 2, 2024 Fri7:51 ambefore market openDec 31, 2023$14.3B−5% y/y$0.46−67% y/y
Show all 12 reports since 2024Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

AbbVie: 15-year financials

202561,16015,0754,22617,81611,657
202456,3349,1374,27817,83211,025
202354,31812,7574,86322,06210,539
202258,05418,11711,83624,24810,043
202156,19717,92411,54221,9909,261
202045,80411,3634,61616,7907,716
201933,26612,9837,88212,7726,366
201832,7536,3835,68712,7895,580
201728,2169,5455,3099,4314,107
201625,6389,3405,9536,5623,717
201522,8597,5375,1447,0033,294
201419,9603,4111,7742,9372,661
201318,7905,6644,1285,7762,555
201218,3805,8175,2756,012—
201117,4443,6203,4335,891—

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.

AbbVie: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
2025133,960−3,27067,0025,22929,06243,289
2024135,1613,32566,8415,52425,58238,749
2023134,71110,36059,24512,81433,00237,841
2022138,80517,25463,1299,20128,46329,538
2021146,52915,40875,9769,74627,92835,194
2020150,56513,07684,9828,44924,17328,661
201989,115−8,17267,23339,92449,51915,585
201859,352−8,44640,3107,28916,94517,239
201770,7865,09737,3689,30321,22316,641
201666,0994,63636,8425,10016,1879,781
201553,0503,94531,6718,39916,31410,894
201427,5131,74214,9778,34816,08111,393
201329,1984,49214,7239,59517,8486,879
201227,008−35015,6725,90115,3546,776
2011———27——

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated14,87113,812+1,059
· incl. D&A (non-cash add-back)depreciation & amortization574559
· incl. stock-based comp (non-cash)share-based compensation770798
Capexpurchases of property & equipment−888−885−3
Free cash flow ≈operating cash flow − capex13,98312,927+1,056
Investing activities, netcapex, acquisitions, securities−11,986−5,180−6,806
· incl. acquisitionsbusinesses net of cash acquired−10,594−204−10,390
Financing activities, netdebt, buybacks, dividends2,685−8,558+11,243
· incl. buybacksrepurchases of common stock−1,503−977−526
· incl. dividends paid−9,227−8,746−481
FX effect on cash−2531−56
Net change in cash5,545105+5,440
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: −$4.6B (−3.1% of total assets). Other S&P 500 companies with negative equity →

Corporate governance

2/2good

  • Mar 2026Per the 2026 proxy, common stock is AbbVie's only voting security, with one vote per share. sec.gov ↗
  • Dec 2025Diluted shares rose 6% over 2020–2025; SBC of $0.96B = 1.6% of $61.2B revenue (2025 10-K). data.sec.gov ↗
2 more facts and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Dec 2025The per-share dividend has risen every year: $4.84 (2020) → $6.65 (2025). data.sec.gov ↗
  • Feb 2026The Legal Proceedings section of the 2025 10-K lists no shareholder class actions or SEC investigations — only product liability and antitrust cases. sec.gov ↗

Scoring: 2.0, no deductions: single share class, dilution +6% over 5 years (<10%), SBC 1.6% of revenue, dividend raised every year, no shareholder suits or SEC cases in the 10-K

Share classes
Single class: common stock is the only voting security, one share = one vote (2026 proxy).
Dilution
Diluted shares +6% over 2020–2025 (mostly the tail of the stock component of the 2020 Allergan deal, at market), SBC 1.6% of revenue — below thresholds.
Disclosure
Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
Dividends
Dividend raised every year since the 2013 spin-off ($4.84 → $6.65 over 2020–2025, XBRL).
Lawsuits & regulators
The 2025 10-K lists only product liability/antitrust suits (Humira, Niaspan, Allergan implants); no shareholder class actions or SEC cases.
Related parties
Committee approval policy for related-party transactions; no material transactions disclosed in the 2026 proxy.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

AbbVie (ABBV) earnings: FAQ

How does AbbVie make money?

AbbVie brought in $17.4 billion of revenue in Q3 2026, up 10.3% year over year. The largest source was Immunology: $9.16 billion, or 53% of the total, followed by Neuroscience ($3.39B, 19%) and Oncology ($1.70B, 10%); other lines add the remaining 18%. Net income for the quarter was $4.22 billion.

When is ABBV's next earnings date?

We have not yet seen an announcement of the date from AbbVie (ABBV). Based on last year's report on Feb 4, 2026, the next report is expected around Feb 3, 2027.

What time does ABBV report earnings?

AbbVie usually reports before market open: its latest results release was filed with the SEC at 7:51 am ET on Oct 30, 2026.

When did ABBV last report earnings?

AbbVie reported Q3 2026 results on Oct 30, 2026.

What has AbbVie guided for FY2026?

Company guidance for FY2026: EPS (non-GAAP) $13.95–13.99 (raised). A year ago (FY2025): revenue $61.2B, EPS (GAAP) $2.36. Source: the company's earnings release (Form 8-K filed Oct 30, 2026).

Where can I find AbbVie's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to ABBV's filings; this page breaks the latest report down in a Sankey chart.

What was ABBV's net income in Q3 2026?

AbbVie reported net income of $4,218M for Q3 2026 (×23 year over year), under US GAAP.

Does AbbVie pay dividends?

Yes. In 2025, AbbVie paid $11,657M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has AbbVie's revenue changed since 2011?

Per its 10-K filings, revenue grew 3.5x: $17,444M in 2011 and $61,160M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · BDX · Q4 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy